These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 19756555)

  • 1. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.
    Wu J; Song Y; Li H; Chen J
    Eur J Clin Pharmacol; 2009 Dec; 65(12):1169-74. PubMed ID: 19756555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
    González Santos P
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
    Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
    Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
    Broeders N; Knoop C; Antoine M; Tielemans C; Abramowicz D
    Nephrol Dial Transplant; 2000 Dec; 15(12):1993-9. PubMed ID: 11096145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
    Jones PH; Davidson MH
    Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin-fibrate combination therapy.
    Shek A; Ferrill MJ
    Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis.
    Choi HD; Shin WG; Lee JY; Kang BC
    Vascul Pharmacol; 2015; 65-66():23-30. PubMed ID: 25451563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
    Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT
    Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A; Simental-Mendía LE; Watts GF; Golledge J
    Atherosclerosis; 2015 May; 240(1):284-96. PubMed ID: 25828270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review.
    Wang D; Wang Y
    Medicine (Baltimore); 2018 Apr; 97(14):e0318. PubMed ID: 29620657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety considerations with fibrate therapy.
    Davidson MH; Armani A; McKenney JM; Jacobson TA
    Am J Cardiol; 2007 Mar; 99(6A):3C-18C. PubMed ID: 17368275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New fibrate use and acute renal outcomes in elderly adults: a population-based study.
    Zhao YY; Weir MA; Manno M; Cordy P; Gomes T; Hackam DG; Juurlink DN; Mamdani M; Moist L; Parikh CR; Paterson JM; Wald R; Yao Z; Garg AX
    Ann Intern Med; 2012 Apr; 156(8):560-9. PubMed ID: 22508733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of fibrates in the United States and Canada.
    Jackevicius CA; Tu JV; Ross JS; Ko DT; Carreon D; Krumholz HM
    JAMA; 2011 Mar; 305(12):1217-24. PubMed ID: 21427374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate.
    Watanabe K; Oda S; Matsubara A; Akai S; Yokoi T
    Toxicol Lett; 2019 Jun; 307():49-58. PubMed ID: 30853469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rhabdomyolysis induced by fenofibrate monotherapy].
    Archambeaud-Mouveroux F; Lopez S; Combes C; Lassandre S; Amaniou M; Teissier MP; Galinat S
    Rev Med Interne; 2006 Jul; 27(7):573-4. PubMed ID: 16716459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
    Pariente A; Labat V; Mansiaux Y; Salvo F; Bégaud B; Raschi E; Faillie JL; Létinier L; Bezin J
    Drug Saf; 2020 Aug; 43(8):767-774. PubMed ID: 32306223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fibrates and risk of venous thromboembolism: Case/no-case study in French pharmacovigilance database].
    Humbert X; Dolladille C; Sassier M; Valnet-Rabier MB; Vial T; Guitton E; Page A; Sole E; Auriche P; Coquerel A; Alexandre J; Fedrizzi S
    Therapie; 2017 Dec; 72(6):677-682. PubMed ID: 28941579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
    Graham DJ; Staffa JA; Shatin D; Andrade SE; Schech SD; La Grenade L; Gurwitz JH; Chan KA; Goodman MJ; Platt R
    JAMA; 2004 Dec; 292(21):2585-90. PubMed ID: 15572716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and risks of the treatment with fibrates--a comprehensive summary.
    Okopień B; Bułdak Ł; Bołdys A
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1099-1112. PubMed ID: 30328735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.